MBRX — Moleculin Biotech Income Statement
0.000.00%
Last trade - 00:00
- $6.91m
- -$3.93m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 17.5 | 19.7 | 23 | 30.6 | 30.1 |
Operating Profit | -17.5 | -19.7 | -23 | -30.6 | -30.1 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -13.4 | -17.4 | -15.9 | -29 | -29.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -13.2 | -17.4 | -15.9 | -29 | -29.8 |
Net Income Before Extraordinary Items | |||||
Net Income | -13.2 | -17.4 | -15.9 | -29 | -29.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -13.2 | -17.4 | -15.9 | -29 | -29.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -29.2 | -26.4 | -8.87 | -15.2 | -14.8 |